AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03077204 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aviator Anterior Cervical Plating System
Description: The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
Study NCT01844778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
Study NCT01844778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution was administered via nebuliser
Study NCT01844778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistimethate
Description: Colistimethate was administered via nebuliser.
Study NCT03399474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 2%
Description: Lidocaine Hydrochloride 2%
Study NCT03399474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 ug/kg
Description: pecedex
Study NCT03399474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection 0.25 ug/kg
Description: pecedex
Study NCT00964561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Valortim
Description: Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
Study NCT00964561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Valortim
Description: Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
Study NCT00964561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Placebo Valortim
Description: Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
Study NCT00614484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
Study NCT01356654 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Application of Transcranial direct current stimulation (TDCS)
Description: Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
Study NCT01356654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct current stimulation
Description: Application of true TDCS for 20min, 4 times a week for 4 weeks.
Study NCT04287738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigated Care
Description: Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
Study NCT02184221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency stimulation
Description: The parameter of DMS: alpha frequency
Study NCT02475928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc gluconate
Description: Zinc supplementation plus nutritional education
Study NCT02475928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00614484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
Study NCT00614484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
Study NCT03973294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT-measurement
Description: The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface.
Study NCT01331291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: Taken orally
Study NCT02475928 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional education
Study NCT02475928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Study NCT02184221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency stimulation
Description: The parameter of DMS: 0.5Hz
Study NCT00368264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
Study NCT00368264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: azathioprine (2 mg/kg) plus four placebo infusions
Study NCT01284283 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Scandinavian Total Ankle Replacement System (STAR Ankle)
Description: For total ankle replacement
Study NCT00264641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Hyperinsulinaemic induced hypoglycaemia
Study NCT01811927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-Kinetic Energy Stent
Description: Bare-metal stent
Study NCT03790527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBM training
Description: participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
Study NCT03790527 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
Study NCT01862887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 24 mg, single dose
Study NCT01862887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablet, 400 mg, single dose
Study NCT01862887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, PH-797804 matched placebo, single dose
Study NCT03801564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Treatment Group (PRP)
Description: EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
Study NCT03801564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Treatment Group (HA)
Description: REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
Study NCT00353405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
Study NCT00353405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: Mass media provides messages that support sexual health skills.
Study NCT00441168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
Study NCT00441168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
Study NCT00441168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: vincristine: 0.4mg IV push on days 1 to 4
Study NCT04280978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABI ABC
Description: The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes.
Study NCT01189045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
Study NCT00353405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group received no social skills training and no media mass media messages.
Study NCT02734810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase Powder for Oral Solution
Description: Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
Study NCT02143908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lysine supplementation
Study NCT02143908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00476021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing IUD (Mirena)
Description: levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
Study NCT00476021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (Mirena)
Description: levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
Study NCT01871610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET amyloid binding imaging
Study NCT04472936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single catheter approach
Description: Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is >80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
Study NCT04472936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional approach
Description: Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
Study NCT02526407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing
Description: Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
Study NCT02526407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group play
Description: Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
Study NCT02140437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Adding fulvestrant to the standard endocrine therapy, anastrozole
Study NCT02140437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: standard endocrine therapy
Study NCT02140437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: standard endocrine therapy
Study NCT02558790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Threonic Acid Magnesium Salt (L-TAMS)
Study NCT03642392 — intervention group
Intervention type: OTHER
Intervention: Identification and treatment of early tendinopathy
Description: Participants receive initial guidance about load reduction when tendinopathy
Study NCT01175733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
Study NCT02723968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT
Description: At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
Study NCT02723968 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HGPIV diagnosis test
Study NCT02723968 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HOMAR-IR diagnosis test
Study NCT03772847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginkgolide
Description: ginkgolide plus alteplase
Study NCT03662984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofibrate 100Mg Tablet
Description: Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
Study NCT03662984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: To compare ciprofibrate
Study NCT00655967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate (Campral)
Description: During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above).
Study NCT00655967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
Study NCT03617783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotin
Description: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
Study NCT03617783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo-OEI
Study NCT05099250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: local anesthetic agent
Study NCT05099250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: local anesthetic agent
Study NCT05099250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
Study NCT05099250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: medical solution
Study NCT05099250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: medical solution
Study NCT00128401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Study NCT00128401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01350245 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
Study NCT01350245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
Study NCT01350245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
Study NCT01350245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Started the day before the transplant to prevent graft versus host disease (GVHD)
Study NCT01350245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Started the day before the transplant to prevent graft-versus-host disease (GVHD)
Study NCT01350245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Description: One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
Study NCT01189045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic Exercise Program
Description: The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
Study NCT03071172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study NCT03071172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).